A Randomized, Double-Blinded, Placebo-Controlled, Study to Evaluate the Safety and Tolerability of BMS-986259 in Stabilized Patients Hospitalized for Acute Decompensated Heart Failure
Latest Information Update: 08 Aug 2022
Price :
$35 *
At a glance
- Drugs FA-relaxin (Primary)
- Indications Acute heart failure; Decompensated heart failure
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 26 Jan 2022 This trial has been discontinued in Poland, according to European Clinical Trials Database record.
- 20 Sep 2021 Status changed from recruiting to completed.
- 02 Feb 2021 Planned End Date changed from 31 Jul 2021 to 6 Apr 2022.